Clofibrate disposition in renal failure and acute and chronic liver disease. 1979

R Gugler, and J W Kürten, and C J Jensen, and U Klehr, and J Hartlapp

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002994 Clofibrate A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) Athromidin,Atromid,Atromid S,Clofibric Acid, Ethyl Ester,Ethyl Chlorophenoxyisobutyrate,Miscleron,Miskleron,Chlorophenoxyisobutyrate, Ethyl
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Gugler, and J W Kürten, and C J Jensen, and U Klehr, and J Hartlapp
January 1976, Lancet (London, England),
R Gugler, and J W Kürten, and C J Jensen, and U Klehr, and J Hartlapp
December 1980, Biochemical pharmacology,
R Gugler, and J W Kürten, and C J Jensen, and U Klehr, and J Hartlapp
October 2007, Hemodialysis international. International Symposium on Home Hemodialysis,
R Gugler, and J W Kürten, and C J Jensen, and U Klehr, and J Hartlapp
December 1977, Clinical nephrology,
R Gugler, and J W Kürten, and C J Jensen, and U Klehr, and J Hartlapp
January 1980, Therapie,
R Gugler, and J W Kürten, and C J Jensen, and U Klehr, and J Hartlapp
January 1990, Nephron,
R Gugler, and J W Kürten, and C J Jensen, and U Klehr, and J Hartlapp
December 1980, British medical journal,
R Gugler, and J W Kürten, and C J Jensen, and U Klehr, and J Hartlapp
August 2019, Revue medicale suisse,
R Gugler, and J W Kürten, and C J Jensen, and U Klehr, and J Hartlapp
December 1975, Lancet (London, England),
R Gugler, and J W Kürten, and C J Jensen, and U Klehr, and J Hartlapp
January 1981, European journal of clinical pharmacology,
Copied contents to your clipboard!